Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

1331 publications found

  1. Carlini BH, Kellum LB, Garrett SB, Williams JR. Cannabis-related problems, adverse events, clinical experiences and barriers to intervening: Perspectives of health care providers in Washington State. Substance Use & Addiction Journal 2026;47(3):852-863. [doi: 10.1177/29767342261426116] PMID: 41910114
  2. Janson S, Newman A, Banta-Green CJ, Glick SN, Tinsley J, Owens MD. Substance use treatment utilization and unmet demand among recently incarcerated syringe services program participants in Washington state. Harm Reduction Journal 2026 (in press). [doi: 10.1186/s12954-026-01512-z]
  3. Gordon AJ, Hatch MA, Kropp FB, Liebschutz JM, Mooney LJ, Cochran G. Twenty-five years of the NIDA clinical trials network and the future of addiction research. Journal of Substance Use & Addiction Research 2026: 210140 (in press). [doi: 10.1016/j.josat.2026.210140] PMID: 42893770
  4. Dawson D, Hall W, Goodwin I, Carlini BH, Lubman DI, Hammond D, Freeman TP, Lorenzetti V. Exploring THC labelling preferences to communicate the strength of cannabis products: Insights from U.S. consumers. International Journal of Drug Policy 2026;147:105076. [doi: 10.1016/j.drugpo.2025.105076] PMID: 41442927
  5. Cioffi C, Baloh J, Brunner M, Cheng H, DiFiore E, Davis AD, Fenstemark C, Fisher S, Finlayson R, Franz B, Franz D, Hosseini MA, Rains AN, Schmidt A, Smith C, Vest N, Hartzler B, CTN Implementation Strategies Workgroup. A scoping review of implementation strategies to reduce stigma toward people who use substances in healthcare settings. Journal of Substance Use and Addition Treatment 2026 (in press). [doi: 10.1016/j.josat.2026.210005] PMID: 42069061
  6. Winstead T, Newman A. Syringe Services Program Participants’ Perceptions, Concerns, and Experiences of Medications for Opioid Use Disorder (MOUD). Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2026
  7. Carlini BH, Williams JR, Garrett SB, Hammond D. People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: A study in WA State, USA. Community Mental Health Journal 2026;62:889-895. [doi: 10.1007/s10597-025-01579-1]
  8. Newman A, Banta-Green CJ. Safer Smoking Supplies – Use, Engagement, and Association with Decreased Injecting in Washington State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2026.
  9. Hartzler B, Brunner M, Fokuo JK, Ostacher MJ, Pagano A, Rutkowski BA, Vest RA, Masson CL. There and back again: Continuing efforts via regional partnership to promote workforce awareness of scientific advancements in addiction care. Journal of Substance Use and Addiction Treatment 2026 (in press). [doi: 10.1016/j.josat.2026.209905] PMID: 41554458
  10. Leyde S, Bell C, Harris C, Wan C, Nye E, Simon CB, Hoog J, Kennedy AJ, Hartzler B, Tsui JI, Fockele C. “It’s not a one-size-fits-all”: Patient perspectives on contingency management and community reinforcement approach for methamphetamine use disorder in permanent supportive housing. Journal of Health Care for the Poor and Underserved 2026;37(2):705-722. [doi: 10.1353/hpu.2026.a992138] PMID: 42290360
  11. Hartzler B, Peng L, Cooke A, Kunkel L, Stack E, Leahy J, Cook R, Hildebran C, Hoffman K, Verbeck J, Nugent M, Leichtling G, Smith Payne K, McIlveen JW, Korthuis PT. Reason to expand the contingency management workforce: Coaching-to-criterion results for addiction professionals and peer specialists. Substance Use & Addiction Journal 2026;47(2):541-548. [doi: 10.1177/29767342251363007] PMID: 40908764
  12. Iacobelli NP, Estrella L, Owens MD, Bhatraju EP, Gojic AJ, Kennedy D, Chander G, Tsui JI. “You’re doing it because your freedom is on the line”: a qualitative study exploring how people who use opioids and methamphetamine navigate legal involvement and carceral treatment for substance use disorder. Harm Reduction Journal 2026; 23, 30. [doi: 10.1186/s12954-025-01378-7] PMID: 41547813
  13. Salinsky LM, Diaz KC, Fox JL, Panh SM, Ferguson SM. Fentanyl, methamphetamine and polysubstance use differentially affect locomotor sensitisation and social behaviour in rats: Psychedelic treatment reverses social deficits. Addiction Biology 2026;31(3):e70132. [doi: 10.1111/adb.70132]
  14. Whiteside LK, Lovett K, Nye E, Engstrom A, Hall J, Field C, Haegerty P, Palinkas LA, McGovern M, Banta-Green CJ, Zatzick D. Emergency department longitudinal integrated care (EDLINC) study: Protocol for a pragmatic effectiveness randomized clinical trial. Contemporary Clinical Trials 2026 (in press). [doi: 10.1016/j.cct.2026.108400] PMID: 42419503
  15. Paschen-Wolff MM, Laschober TC, Spector AY, Ertl MM, Nelson CM, Hatch MA, Lancaster C, Wright L, Tross S. “PrEP is always on the table”: Mixed methods study of provider willingness to refer/link clients to PrEP in community sexual health and drug use-related programs. Journal of HIV/AIDS & Social Services 2025 (in press). [doi: 10.1080/15381501.2025.2545265]
  16. Bhat A, Curran MC, Lohr MJ, Smith H, Blanchard B, Stoner SA, Grant T, Grote N. Integrating a brief behavioral intervention into case management for mothers with perinatal substance use disorder: Nonrandomized pilot feasibility study. JMIR Formative Research 2025;9:e75132. [doi: 10.2196/75132] PMID: 41468592 PMCID: PMC12753098
  17. Becker SJ, Janssen T, Souza T, Hartzler B, Rash CJ, DiClemente-Bosco K, Garner BR. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): Results of a 28-site cluster-randomized type 3 hybrid trial. Implementation Science 2025;21(1):9. [doi: 10.1186/s13012-025-01473-0] PMID: 41361474 PMCID: PMC12870086
  18. Jha C, Donovan DM. Harm reduction without supportive policing: Experiences of drug users in Nepal. Journal of Social, Behavioral, and Health Sciences 2025;19:1-17. [doi: 10.5590/JSBHS.2025.19.1678]
  19. Tross S, Laschober TC, Paschen-Wolff M, Ertl M, Nelson CM, Wright L, Lancaster C, Feaster DJ, Monger M, Toal P, Fegley JP, Meche D, Hankey C, Woodhouse C, Spector A, Dresser L, Moran L, Jelstrom E, Haynes L, Shoptaw S, Hatch MA. Willingness to use oral and long-acting injectable PrEP in substance-using men who have sex with men (SU-MSM) in high HIV incidence Southern U.S. cities: A NIDA Clinical Trials Network study. AIDS and Behavior 2025;29(4):1192-1204. [doi: 10.1007/s10461-024-04594-7]
  20. Owens, MD. Evaluation of the City of Seattle Ordinance 126896 on Controlled Substances: Final Report [to the Seattle Office of Inspector General]. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, December 2025.
  21. Siebert SL, Owens MD, Folk JB, Moore KE. Criminal justice staff’s professional quality of life and interactions with justice-involved individuals: The moderating role of stigma. Deviant Behavior 2025;46(6):803-819. [doi: 10.1080/01639625.2024.2372419] PMID: 40519513
  22. Kellum LB, Carlini BH, Garrett S. Assessing Engagement in Cannabis Policy: A Survey of Washington State Elected Officials. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2025
  23. Hunnicut-Ferguson K, Stoner SA, Kable JA, Grant TM, Coles CD. Substance use and mental health symptoms in adults with prenatal alcohol exposure. Neurotoxicology Teratology 2025;109:107436. [doi: 10.1016/j.ntt.2025.107436] PMID: 40032207
  24. Garrett SB, Williams J, Carlini BH, Hammond D. Cannabis consumer patterns, adverse events, and cannabis risk beliefs: A latent profile analysis in WA State. Drug and Alcohol Dependence 2025;273:112728. [doi: 10.1016/j.drugalcdep.2025.112728]
  25. Hartzler B, Doig M, Cooke A, Kunkel L, Peng L, Stack E, Smith Payne K, McIlveen J, Korthuis PT. Training addiction professionals and peers to deliver contingency management via a coaching-to-criterion process: Results of a non-inferiority analysis. Substance Use & Addiction Journal 2025 (in press).
  26. Moore M, Oscadal M. Starting buprenorphine in outpatient settings using a high-dose approach. Journal for Nurse Practitioners 2025;21(1):105260 [doi: 10.1016/j.nurpra.2024.105260]
  27. Newman A, Winstead T, Layman L. “I think one enhances the other”: Use of harm reduction and drug treatment among participants of syringe services programs. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2025
  28. Zinsli KA, Banta-Green CJ, Whiteside LK, Hood J, Kingston S, Tinsley J, Moreno C, Glick SN. Trends and correlates of naloxone possession and use among people who inject drugs in Seattle, Washington. International Journal of Drug Policy 2025;144(Part 1):104272. [doi: 10.1016/j.drugpo.2023.104272] PMID: 38057247
  29. Sladky M, Banta-Green C. Kratom & 7-OH: What do we know about use, safety, and overdose risk? Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, April 2024, updated August 2025.
  30. Paschen-Wolff MM, Campbell ANC, Vasquez A, Kessler J, Jansen K, Arnatt CP, Rosa C, Hebden HM, Radin S, Stately A, Shaw J, Kennedy F, Matthews AG, Venner KL. Conducting an implementation intervention study with American Indian and Alaska native communities: Methodological considerations. Contemporary Clinical Trials 2025:107992. [doi: 10.1016/j.cct.2025.107992] PMID: 40544955
  31. Reiman A, Lessin B. Harm Reduction Approaches with Adolescents Who Use Substances. Routledge, 2025, 172p.
  32. Roll J, Barbosa-Leiker C, Carlini B, Fuchs R, McDonell M, Stella N, Riordan DG, Dyedov R, Ellioff K, Reid S. Cannabis Research in Washington State: A Report for the Washington State Department of Commerce. Seattle, WA: Washington State Academy of Sciences, January 2025, 24 p.
  33. Dillard DA, Hebert LE, Dirks LG, Shaw JL, Trinidad SB, Lillie K, Donovan DM, Burke W, Ludman EJ. Attitudes about alcohol misuse among Alaska Native people in a Tribal health care system. Journal of Addiction Medicine 2025 (in press). [doi: 10.1097/ADM.0000000000001564] PMID: 40928084
  34. Le MH, Laschober TC, Tross S, Paschen-Wolff M, Ertl MM, Wright L, Hatch MA. Attitudes toward and experience with naloxone among people who use drugs in the Southeastern United States. International Journal of Drug Policy 2025;139:10479. [doi: 10.1016/j.drugpo.2025.104769] PMID: 40073718
  35. Cooke A, Stack E, Peng L, Cook R, Hartzler B, Leichtling G, Hildebran C, Leahy JM, Payne KS, Kunkel LE, Hoffman K, Korthuis PT. The peers expanding engagement in stimulant harm reduction with contingency management study: A protocol paper. Addiction Science & Clinical Practice 2025;20:48. [doi: 10.1186/s13722-025-00577-8] PMID: 40495203 PMCID: PMC12150483
  36. Simon CB, Hus C, Prado MG, West II, Kwun CGC, LeMaster JW, Hatch MA, Tong ST, Stephens KA. Examining removal of federal waiver restrictions to prescribing buprenorphine in primary care. Journal of the American Board of Family Medicine 2025;38(3):752-756. [doi: 10.3122/jabfm.2024.240453R1] PMID: 41115754
  37. Lovett K, Zatzick D, Palnikas LA, Engstrom A, Nye E, Field C, McGovern M, Parrish C, Banta-Green CJ, Whiteside LK. Adapting to the fentanyl epidemic: Rapid qualitative observations and derived clinical and research implications from the Emergency Department Longitudinal Integrated Care (ED-LINC) randomized clinical trial. Psychiatry 2025;88(4):333-350. [doi: 10.1080/00332747.2025.2472429] PMID: 40100166
  38. ADAI, Research with Expert Advisors on Drug Use (READU), Owens M. The Community-Law Enforcement Aligning in Response to Substance use (CLEARS) Project. Summary of Process Evaluation Findings. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2025, 28 p.
  39. Ertl MM, Woodhouse C, Meche D, Forrest DW, Fegley J, Paschen-Wolff M, Laschober TC, Hatch MA, Nelson CM, Wright L, Tross S. Using structural modeling to examine barriers and facilitators of HIV pre-exposure prophylaxis willingness and length of use in men who have sex with men who use substances in eight Southern U.S. cities. AIDS Patient Care and STDS 2025;39(6):245-256. [doi: 10.1089/apc.2025.0036] PMID: 40401366 PMCID: PMC12172640
  40. Lancaster C, Laschober TC, Nelson CM, Hatch MA, Paschen-Wolff MM, Ertl MM, Wright L, Tross S. Predicting willingness to use MOUD: An application of the theory of reasoned action and theory of planned-behavior. Journal of Drug Issues 2025 (in press). [doi: 10.1177/00220426251395179]
  41. Peng L, Stack E, Cooke A, Hartzler B, Cook R, Leichtling G, Hildebran C, Leahy J, Smith Payne K, Kunkel L, Hoffman K, Korthuis PT. Centering peers in design and training for a peer-delivered contingency management program for self-identified harm reduction and treatment goals. Harm Reduction Journal 2025;22(suppl 1):72. [doi: 10.1186/s12954-025-01213-z] PMID: 40329274 PMCID: PMC12057027
  42. Ball A, Winstead T, Singh S, Floyd A, Banta-Green C. Adolescent and young adult access to opioid use disorder care. Pediatrics 2025;156(1):e2024070224. [doi: 10.1542/peds.2024-070224] PMID: 40499923
  43. Orozco K, Laschober TC, Tross S, Ertl MM, Paschen-Wolff MM, Nelson CM, Lancaster C, Hatch MA. Future pandemic preparedness: conceptualizing vaccine willingness in drug-using populations during COVID-19 in Southeastern U.S. cities. Journal of HIV/AIDS & Social Services 2025 (in press). [doi: 10.1080/15381501.2025.2591675]
  44. Perkins T, Lee B, Mackin J, Donovan D, Rushing SC, Caughlan C, Gchachu Kakuska A, Walker L. Healing of the Canoe: Preliminary suicide prevention outcomes among participating and non-participating youth. Prevention Science 2025;26:740-750. [doi: 10.1007/s11121-025-01806-x] PMID: 40289054
  45. Petersky S, Banta-Green C. Perceptions of Substance Use in Permanent Supportive Housing: Results from the 2024 WA State PerCH Staff Survey. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, March 2025, 10p.
  46. Paschen-Wolff MM, Tross S, Nelson CM, Hatch MA, Meche D, Ertl MM, Wright L, Laschober TC. Factors associated with PrEP awareness and use among men who have sex with men who use drugs in the Southern United States. AIDS Care 2025;37(1):21-32. [doi: 10.1080/09540121.2024.2438923] PMID: 39651544
  47. Owens MD, Adwell A, Singh S, Osilla K, Tweedy M, Tsui J. “All I want is the best for my brother”: Interest in a Community Reinforcement and Family Training (CRAFT)-based group intervention among concerned significant others of individuals on office-based medications for opioid use disorder. BMC Psychiatry 2025;25:748. [doi: 10.1186/s12888-025-07132-4] PMID: 40745287 PMCID: PMC12312360
  48. Hatch MA, Ertl M, Closs D, Keeshin S, Feinberg J, Orozco K, Tross S. HIV prevention in syringe service programs since the start of COVID-19: Where do we go from here? Current HIV/AIDS Reports 2025;22(1):13. [doi: 10.1007/s11904-024-00721-0] PMID: 39812953 PMCID: PMC12640190
  49. Heidari O, Banta-Green CJ. Expanding access to medications for opioid use disorder: Federal policy is only a part of the solution [editorial]. American Journal of Public Health 2024;114(7):693-695. [doi: 10.2105/AJPH.2024.307715] PMID: 38838294 PMCID: PMC11153965
  50. Douaihy A, Donovan DM, Daley DC. Twelve-step facilitation approaches. IN: Miller SC, Rosenthal RN, Levy S, Saxon AJ, Tetrault JM, Wakeman SE (eds.). THE ASAM PRINCIPLES OF ADDICTION MEDICINE (7th edition). Philadelphia: Wolters Kluwer, p. 1213-1218
  51. Allen JA, Benowitz N, Blumenthal R, Carlini BH, Cooper Z, Fong T, Halpern-Felsher B, Johnson RM, Ling P, Pacula R, Piomelli D, Silver LD, Young-Wolff K. Report and Recommendations of the High Potency Cannabis Think Tank to the State of California. Sacramento, CA: California Department of Public Health, October 2024, 42p.
  52. Irwin AN, Gray M, Ventricelli D, Boggis JS, Bratberg J, Floyd AS, Silcox J, Hartung DM, Green TC. “I go out of my way to give them an extra smile now:” A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials. Research in Social and Administrative Pharmacy 2024;20(5):512-519. [doi: 10.1016/j.sapharm.2024.02.001] PMID: 38395644 PMCID: PMC10981567
  53. Blough MJ, Rocha A, Bratberg J, Silcox J, Bolivar D, Floyd AS, Gray M, Green TC. The cost of safe injection: Insights on nonprescription syringe price variability from systematic secret shopping. Substance Use & Addiction Journal 2024;45(2):201-210. [doi: 10.1177/29767342231217831] PMID: 38258818
  54. Douaihy A, Daley DC, Donovan DM. Relapse prevention: Clinical models and intervention strategies. IN: Miller SC, Rosenthal RN, Levy S, Saxon AJ, Tetrault JM, Wakeman SE (eds.). THE ASAM PRINCIPLES OF ADDICTION MEDICINE (7th edition). Philadelphia: Wolters Kluwer, p. 1219-1235
  55. Carpenter KM, Walker DD, Mullis K, Berlin HM, Short E, Javitz HS, Carlini BH. Testing a brief quitline intervention for tobacco cannabis co-users: A randomized controlled pilot study. Tobacco Use Insights 2024;17:117917x241261302. [doi: 10.1177/1179173X241261302] PMID: 38873657 PMCID: PMC11171437
  56. Hatch MA, Laschober TC, Paschen-Wolff M, Ertl MM, Nelson CM, Wright L, Lancaster C, Feaster DJ, Forrest D, Hankey C, Monger M, Fegley JP, Irving R, Young C, Rose J, Spector A, Dresser L, Moran L, Jelstrom E, Tross S. PrEP for people who use opioids: A NIDA Clinical Trials Network survey study in Southern U.S. cities where HIV incidence is high. Drug and Alcohol Dependence 2024;257:111133. [doi: 10.1016/j.drugalcdep.2024.111133] PMID: 38447393 PMCID: PMC11131129
  57. Floyd AS, Silcox J, Strickler G, Nong T, Blough M, Bolivar D, Rabin M, Bratberg J, Irwin AN, Hartung DM, Hansen RN, Bohler R, Green TC. Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews. Drug and Alcohol Dependence Rep 2024;11:100243. [doi: 10.1016/j.dadr.2024.100243]
  58. Pusnik A, Hartzler B, Vjorn O, Rutkowski BA, Chaple M, Becker S, Freese T, Nichols M, Molfenter T. Comparison of use rates of telehealth services for substance use disorder during and following COVID-19 safety distancing recommendations: Two cross-sectional surveys. JMIR Mental Health 2024;11:e52363. [doi: 10.2196/52363] PMID: 39136186 PMCID: PMC11331268
  59. Kingston S, Newman A, Banta-Green C, Glick S. Results from the 2023 WA State Syringe Services Program Health Survey. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, April 2024
  60. Ledgerwood DM, Stott MC, Quesada S, Sontag M, Beck RM, Johnson D, McDonell MG, Johnson D, DePhilippis D, Donnelly S, Hartzler B, Nauts T, Novak M, Peck J, Rash CJ. Implementing contingency management into rural recovery housing: Recommendations of a professional advisory panel. American Journal of Drug and Alcohol Abuse 2024;50(6):831-840. [doi: 10.1080/00952990.2024.2387725] PMID: 39172119
  61. Hatch MA, Laschober TC, Ertl MM, Paschen-Wolff MM, Norman G, Wright L, Tross S. Program director reports of COVID-19 lockdown-driven service changes in community-based STI clinics and syringe services programs in the southeastern U.S. AIDS Education and Prevention 2024;36(2):129-40. [doi: 10.1521/aeap.2024.36.2.129] PMID: 38648174 PMCID: PMC11608127
  62. Carlini BH, Harwick RH, Williams JR. Language Matters: Cannabis and Tobacco Use Among Youth of Diverse Racial/Ethnic Backgrounds. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, July 2024.
  63. Carlini BH, Garrett SB, Matos P, Nims LN, Kestens Y. Identifying policy options to regulate high potency cannabis: A multiple stakeholder concept mapping study in Washington State, USA. International Journal of Drug Policy 2024;123:104270. [doi: 10.1016/j.drugpo.2023.104270] PMID: 38043404
  64. Torres VN, Williams EC, Ceballos RM, Donovan DM, Ornelas IJ. Discrimination, acculturative stress, alcohol use and their associations with alcohol-related consequences among Latino immigrant men. Journal of Ethnicity in Substance Abuse 2024;23(1):150-165. [doi: 10.1080/15332640.2022.2077273] PMID: 35634786
  65. Khan Z, Harris JR, Dearden L, Strait M, Treend K, Glesmann H, Carlini BH. Trends in varenicline use for tobacco cessation, and their implications. Journal of the American Pharmacists Association 2024;64(4):102102. [doi: 10.1016/j.japh.2024.102102] PMID: 38649095
  66. Petersky S, Banta-Green CJ. Results from the 2024 WA State Permanent Supportive Housing Perceptions and Community Health Survey. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, September 2024
  67. Owens MD, McKee M, Rickert C, Rogel B, Starnes B. Development and exploratory evaluation of substance use and substance use disorder training for the Washington State Basic Law Enforcement Academy. Policing 2024;18:paae091. [doi: 10.1093/police/paae091]
  68. Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S. Community-based medications first for opioid use disorder – Care utilization and mortality outcomes. Substance Abuse and Rehabilitation 2024;15:173-183 [doi: 10.2147/sar.s475807]
  69. Harwick RM, Carlini BH, Williams JR. Food hardship as a strong predictor of tobacco and cannabis use among youth in WA state. Children and Youth Services Review 2024;157:107427. [doi: 10.1016/j.childyouth.2023.107427]
  70. Nelson LA, Shinagawa E, Garza CM, Squetimkni-Anquoe A, Jeffries I, Rajeez V, Taylor EM, Taylor S, Eakins D, Parker ME, Ubay T, King V, Duffing-Romero X, Park S, Saplan S, Clifasefi SL, Lowe J, Collins SE. A pilot study of virtual Harm Reduction Talking Circles for American Indian and Alaska Native adults with alcohol use disorder. Journal of Community Psychology 2024;52(6):739-761. [doi: 10.1002/jcop.23127] PMID: 38932516
  71. UW Center for Community-Engaged Drug Education, Epidemiology & Research (CEDEER), Banta-Green CJ. Washington State Drug Brief: BTMPS – A New Substance Found in Community Drug Checking Samples. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, September 2024
  72. Winstead T, Singh S, Floyd A, Banta-Green C. Contingency Management for Methamphetamine Use: Qualitative Interviews at Harm Reduction Programs. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, March 2024
  73. Green TC, Silcox J, Boliver D, Gray M, Floyd AS, Irwin AN, Hansen RN, Hartung DM, Bratberg J. Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains. Journal of the American Pharmacists Association 2024;64(1):71-78. [doi: 10.1016/j.japh.2023.10.014] PMID: 37863398 PMCID: PMC11014459
  74. Carlini BH, Kellum LB, Garrett SB, Nims LN. Threaten, distract, and discredit: Cannabis industry rhetoric to defeat regulation of high-THC cannabis products in Washington State, USA. Journal of Studies on Alcohol and Drugs 2024;85(3):322-329. [doi: 10.15288/jsad.23-00277] PMID: 38270913 PMCID: PMC11218453
  75. LoParco CR, Cui Y, McCready D, Romm KF, Yang TY, Rossheim ME, Carlini B, Vinson K, Cavazos-Rehg P, Berg CJ. State requirements for non-medical US cannabis retail personnel. Journal of Public Health Management and Practice 2024;30(4):517-525. [doi: 10.1097/PHH.0000000000001892] PMID: 38833682
  76. Frank ND, Banta-Green CJ, Guthrie BL, Kingston S, Tinsley J, Whiteside L, Glick SN. Emergency room utilization and methamphetamine overdose symptoms among syringe services program participants in Washington State. Substance Use & Misuse 2024;59(7):1012-1019. [doi: 10.1080/10826084.2024.2317148] PMID: 38369494
  77. Owens M, Borges A, McGrath J, Stern MF. The Status of Medications for Opioid Use Disorder (MOUD) Provision in Washington State Jails, 2021. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2023
  78. Floyd AS, Silcox J, Cousin E, Irwin AN, Gray M, Bolivar D, Bratberg J, Arnold J, Al-jammali Z, Hansen RN, Hartung DM, Green TC. Readiness of community pharmacies to implement an opioid safety intervention. Journal of the American Pharmacists Association 2023:63(1):275-283.e1. [doi: 10.1016/j.japh.2022.10.031] PMID: 36496310 PMCID: PMC9870924
  79. Gray M, Shin SS, Silcox J, Flores D, Bolivar D, Irwin AN, Floyd AS, Bratberg J, Boggis JS, Hartung DM, Green TC. “Like it was just everyday business”: A qualitative study of pharmacy-based naloxone and syringe customer experience. Journal of the American Pharmacists Association 2023;63(3):838-846. [doi: 10.1016/j.japh.2023.01.013] PMID: 36872182 PMCID: PMC10198806
  80. Winstead T, Newman A, Maroon E, Banta-Green C. Unmet Needs, Complex Motivations, and Care for People Using Fentanyl in Washington State: A Qualitative Study. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2023
  81. Chaple MJ, Kunins HV, Nass MD, Benjamin AC, Viel CR, Bertone P, Marker L, Warren P, Hartzler B. Exploring the impact of external facilitation using evidence-based implementation strategies for increasing motivational interviewing capacity among outpatient substance use treatment providers. Journal of Behavioral Health Services & Research 2023;51:185-202. [doi: 10.1007/s11414-023-09871-2] PMID: 38030934
  82. Kingston S. Overview and Perspectives of Syringe Services Programs in Washington State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, February 2023
  83. Hartzler B. Is it time to broaden community dissemination of cognitive-behavioral therapy for substance use disorders: Charting pathways to ascend the remaining mountainside [commentary]. Clinical Psychology: Science and Practice 2023;30(2):147-149. [doi: 10.1037/cps0000138]
  84. Peavy KM, Adwell A, Owens MD, Banta-Green CJ. Perspectives on medication treatment for opioid use disorder in adolescents: Results from a provider learning series. Substance Use & Misuse 2023;58(1):160-162. [doi: 10.1080/10826084.2022.2136493] PMID: 36371698
  85. Banta-Green C, Duncan M. Treatment Medications for Fentanyl Use Disorder: Prescriber Practices and Support Needs in WA State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, September 2023
  86. Fockele CE, Morse SC, van Draanen J, Leyde S, Banta-Green C, Huynh LN, Zatzick A, Whiteside LK. “That line that just kept moving”: Motivations and experiences of people who use methamphetamine. West J Emerg Med 2023;24(2):218-227. [doi: 10.5811/westjem.2022.12.58396] PMID: 36976607 PMCID: PMC10047723
  87. Carlini B, Garrett S, Kellum L, Nims L. Cannabis Research Report, 2021-2023. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, August 2023
  88. Kingston S, Biamont B, Banta-Green C. Community Drug Checking Network. The Use and Impact of Community Drug Checking Services. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, November 2023
  89. Irwin AN, Bratberg J, Al-Jammali Z, Arnold J, Gray M, Floyd AS, Boliver D, Hansen R, Hartun DM, Green TC. Implementation of an academic detailing intervention to increase naloxone distribution and foster engagement in harm reduction from the community clinician. Journal of the American Pharmacists Association 2023;63(1):284-294.e1. [doi: 10.1016/j.japh.2022.12.001] PMID: 36567216 PMCID: PMC9933140
  90. Hall W, Leung J, Carlini BH. Do not let the ideal be the enemy of good enough regulation [commentary]. Addiction 2023;118(6):1009-1010. [doi: 10.1111/add.16201]
  91. Owens MD, Banta-Green CJ, Newman A, Marren R, Takushi R. Insights into a recovery community center model: Results from qualitative interviews with staff and member facilitators from Recovery Cafe in Seattle, Washington. Alcoholism Treatment Quarterly 2023; 41(1):62-75. [doi: 10.1080/07347324.2022.2088323]
  92. Stoner SA, Graham JC, Grant TM. Evaluating outcomes of a three-year case management program for mothers with prenatal substance use according to race/ethnicity, Washington State, 2006–2017. BMC Public Health 2023;23:1832. [doi: 10.1186/s12889-023-16670-z] PMID: 37730578 PMCID: PMC10512570
  93. Boyle HK, Singh S, Lopez G, Jackson KM, Carey KB, Merrill JE. Insights into the context of simultaneous alcohol and cannabis use among young adults. Experimental and Clinical Psychopharmacology 2023;31(3):662-673. [doi: 10.1037/pha0000607] PMID: 36174141 PMCID: PMC10201978
  94. Trinidad SB, Shane AL, Guinn TR, Apok CR, Collier AF, Avey JP, Donovan DM. Cultural adaptation of a sobriety support app for Alaska Native and American Indian people: A qualitative study. JMIR Formative Research 2023;7:e38894. [doi: 10.2196/38894] PMID: 36473107 PMCID: PMC9944154
  95. Salow K, Jack HE, Tinsley J, Banta-Green CJ, Kingston S, Iles-Shih M, Tsui J, Glick S. Racial disparities in use of syringe service programs in King County, WA: A comparison of two cross-sectional surveys. Harm Reduction Journal 2023;20:133. [doi: 10.1186/s12954-023-00868-w] PMID: 37704989 PMCID: PMC10500904
  96. Hancock C, Johnson A, Sladky M, Chen LL, Shushan S, Parchman ML. Integrating MOUD and primary care: Outcomes of a multicenter learning collaborative. Family Medicine 2023;55(7):452-459. [doi: 10.22454/FamMed.2023.643371] PMID: 37450845 PMCID: PMC10622073
  97. Dillard DA, Hebert LE, Shaw JL, Trinidad SB, Dirks LG, Lillie K, Ludman EJ, Donovan D, Burke W. Measuring attitudes about alcohol misuse and dependence among Alaska Native people within a tribal health care system. Journal of Addiction Medicine 2023;17(1):e42-e48. [doi: 10.1097/ADM.0000000000001040] PMID: 36166685
  98. Hartzler B, Gray K, Marx M, Kirk-Lewis K, Payne-Smith K, McIlveen JW. Community implementation of contingency management to address stimulant use. Journal of Substance Use and Addiction Treatment 2023;151:208941. [doi: 10.1016/j.josat.2022.208941]
  99. Park CJ, Freeman LK, Hall NA, Singh S, Carey KB, Merrill JE, DiBello AM, Miller MB. Gender, acculturation, and alcohol-related consequences among college students of color. Journal of American College Health 2023;71(1):44-52. [doi: 10.1080/07448481.2021.1891079] PMID: 33651663 PMCID: PMC8410888
  100. Washington State Health Care Authority, University of Washington Addictions, Drug & Alcohol Institute [Carlini BH, Garrett SB, Nims LN].. High THC Policy | Final Report: Exploring Policy Solutions to Address Public Health Challenges of High THC Products. Engrossed Substitute Senate Bill 5092; Section 215(55); Chapter 334; Laws of 2021. Olympia, WA; Washington State Health Care Authority, December 2022